This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Human T-cell lymphotrophic virus–I (HTLV-I)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic progressive neurologic illness caused by HTLV-I. HAM/TSP is endemic in Brazil1 and, although there are some interregional differences in neurologic manifestations, the main clinical findings are similar to those previously described.1,2
The lifetime risk among HTLV-I carriers to develop HAM/TSP is less than 2%.2 As in several other chronic inflammatory or neurodegenerative diseases, it would be helpful to identify sensitive or specific clinical or complementary tests to detect early pathologic lesions, to follow up disease progression, or to predict which asymptomatic HTLV-I–positive patients will develop HAM/TSP. Recently, a quantitative assessment of muscle spasticity showed subclinical increased lower extremity tone in female commercial sex workers positive for HTLV-I.3 The relevance of this finding to HAM/TSP development remains unknown.3
Viral mRNA of HTLV-I was found in astrocytes of patients with HAM/TSP …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard